马耳他 - 英文 - Medicines Authority

fresenius kabi limited - sodium acetate trihydrate; sodium chloride; potassium chloride; magnesium chloride hexahydrate - solution for infusion - sodium acetate trihydrate 4.63 g; sodium chloride 6.02 g; potassium chloride 0.30 g; magnesium chloride hexahydrate 0.30 g - blood substitutes and perfusion solutions

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - modified liquid gelatine; sodium chloride; magnesium chloride hexahydrate; potassium chloride; sodium (s)-lactate solution - solution for infusion - 3 gram(s) - blood substitutes and plasma protein fractions

菲律宾 - 英文 - FDA (Food And Drug Administration)

n/a; importer: viatris pharmaceuticals, inc.; distributor: viatris pharmaceuticals, inc. - tenofovir alefenamide (as fumarate) - film-coated tablet - 25 mg

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

viatris limited - fentanyl 10.2mg (alkaloid powder) - transdermal patch - 100 mcg/h - active: fentanyl 10.2mg (alkaloid powder) excipient: dimeticone polyolefin film (mediflex 1000) 25 square centimeters polyester release liner (scotchpak 1022) 37.34 square centimeters no-tox white fgn-4194 nt23 silicone adhesive - mylan fentanyl patch is indicated in the management of chronic cancer pain. mylan fentanyl patch is also indicated in the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. it is indicated for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

viatris limited - fentanyl 1.28mg (alkaloid powder) - transdermal patch - 12 mcg/h - active: fentanyl 1.28mg (alkaloid powder) excipient: dimeticone polyolefin film (mediflex 1000) 3.13 square centimeters polyester release liner (scotchpak 1022) 10.16 square centimetres no-tox white fgn-4194 nt23 silicone adhesive - mylan fentanyl patch is indicated in the management of chronic cancer pain. mylan fentanyl patch is also indicated in the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. it is indicated for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

viatris limited - fentanyl 2.55mg (alkaloid powder) - transdermal patch - 25 mcg/h - active: fentanyl 2.55mg (alkaloid powder) excipient: dimeticone polyolefin film (mediflex 1000) 6.25 square centimeters polyester release liner (scotchpak 1022) 13.21 square centimetres no-tox white fgn-4194 nt23 silicone adhesive - mylan fentanyl patch is indicated in the management of chronic cancer pain. mylan fentanyl patch is also indicated in the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. it is indicated for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

viatris limited - fentanyl 5.1mg (alkaloid powder) - transdermal patch - 50 mcg/h - active: fentanyl 5.1mg (alkaloid powder) excipient: dimeticone polyolefin film (mediflex 1000) 12.5 square centimeters polyester release liner (scotchpak 1022) 22.35 square centimeters no-tox white fgn-4194 nt23 silicone adhesive - mylan fentanyl patch is indicated in the management of chronic cancer pain. mylan fentanyl patch is also indicated in the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. it is indicated for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

viatris limited - fentanyl 7.65mg (alkaloid powder) - transdermal patch - 75 mcg/h - active: fentanyl 7.65mg (alkaloid powder) excipient: dimeticone polyolefin film (mediflex 1000) 18.75 square centimeters polyester release liner (scotchpak 1022) 28.45 square centimeters no-tox white fgn-4194 nt23 silicone adhesive - mylan fentanyl patch is indicated in the management of chronic cancer pain. mylan fentanyl patch is also indicated in the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. it is indicated for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

阿拉伯联合酋长国 - 英文 - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

each foil pouch includes a carton containing 1 vial of concentrate (2 ml cyclic olefin polymer vial) and 2 vials of solvent (2 ml cyclic olefin polymer vial) -

阿拉伯联合酋长国 - 英文 - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

500 ml polyolefin freeflex bag -